PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

• R. Vij,
• H. Schade,
• S. Trudel,
• A. C. Chang,
• J. Huang,
• D. Samineni,
• T. Sumiyoshi,
• J. Tsai,
• T. Wong,
• S. J. Harrison

Affiliations

R. Vij

1 Washington University, St. Louis, MO

H. Schade

2 Colorado Blood Cancer Institute, Denver, CO, United States of America

S. Trudel

3 Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada

A. C. Chang

4 Genentech, Inc., South San Francisco, CA, United States of America

J. Huang

4 Genentech, Inc., South San Francisco, CA, United States of America

D. Samineni

4 Genentech, Inc., South San Francisco, CA, United States of America

T. Sumiyoshi

4 Genentech, Inc., South San Francisco, CA, United States of America

J. Tsai

4 Genentech, Inc., South San Francisco, CA, United States of America

T. Wong

4 Genentech, Inc., South San Francisco, CA, United States of America

S. J. Harrison

5 Peter MacCallum Cancer Center and Royal Melbourne Hospital, and Sir Peter MacCallum Dept of Oncology, University of Melbourne, Melbourne, VIC, Australia